Prognostic impact of human epidermal growth factor-2 (HER2) status on overall survival (OS) of advanced gastric cancer (AGC) patients (pts) treated with standard chemotherapy without trastuzumab as a first-line treatment: A Japanese multicenter collaborative retrospective study.

Tomohiro Nishina,Nozomu Fuse,Takeshi Kuwata,Shigenori Kadowaki,Eiji Shinozaki,Nozomu Machida,Satoshi Yuki,Akira Ooki,Shinya Kajiura,Takahiro Goji,Takeharu Yamanaka,Takahide Sasaki,Kohei Shitara,Yasutoshi Kuboki,Takayuki Yoshino,Atsushi Ochiai,Atsushi Ohtsu

Prognostic impact of human epidermal growth factor-2 (HER2) status on overall survival (OS) of advanced gastric cancer (AGC) patients (pts) treated with standard chemotherapy without trastuzumab as a first-line treatment: A Japanese multicenter collaborative retrospective study.

2017

Tomohiro Nishina
Nozomu Fuse
Takeshi Kuwata
Shigenori Kadowaki
Eiji Shinozaki
Nozomu Machida
Satoshi Yuki
Akira Ooki
Shinya Kajiura
Takahiro Goji
Takeharu Yamanaka
Takahide Sasaki
Kohei Shitara
Yasutoshi Kuboki
Takayuki Yoshino
Atsushi Ochiai
Atsushi Ohtsu

4075 Background: The prognostic impact of HER2 status on OS of AGC pts treated with standard chemotherapy without trastuzumab for first-line treatment remains controversial. This study investigated...

Keywords:

Cancer
Trastuzumab
Pathology
Retrospective cohort study
Oncology
Human epidermal growth factor
Medicine
Chemotherapy
Internal medicine
first line treatment
overall survival
advanced gastric cancer

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations